Combining optimized safety and security, Schreiner MediPharm's Cap-Lock plus RFID ensures product integrity while increasing ...

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) approved a ...

Omvoh now offers patients a simplified maintenance experience with one monthly injection, replacing the previous two-injection regimen Omvoh single-injection dosing ...

Discover Regeneron’s Q3 2025 earnings: strong Dupixent, Libtayo & EYLEA HD growth, R&D updates, plus key manufacturing and regulatory challenges.

Argenx (($ARGX)) has held its Q3 earnings call. Read on for the main highlights of the call. Argenx’s recent earnings call painted a picture of ...

The approval for the CRSwNP indication was based on data from the randomized, double-blind, placebo-controlled WAYPOINT trial.

Bayer AG (($BAYRY)) announced an update on their ongoing clinical study. Bayer AG has initiated an observational study titled ‘Drug Utilization ...

Regeneron investors should embrace the fact that Eylea is no longer a growth product and focus on the rest of the commercial ...

On track to submit seronegative gMG sBLA by year-end and report ADAPT-OCULUS results in 1H26 – supporting pursuit of broadest MG label of any biologic Five registrational study readouts expected in ...

Despite the rejection, analysts saw Regeneron’s use of an alternate filler for Eylea HD as a positive development, with BMO Capital Markets noting that this could signal the end of manufacturing ...

Investing.com -- Argenx (EBR: ARGX) shares climbed more than 2% on Thursday after the Belgian biopharmaceutical company reported third-quarter results that exceeded forecasts, led by stronger product ...